Clinical trials: Haploidentical Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether a repeat dose administration of ATIR101 is safe and effective when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02500550
- Testing
- ATIR101, Haploidentical hematopoietic stem cell transplantation (HSCT), TBI regime
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 15 people
- Sponsor
- Kiadis Pharma
AML, MDS
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating…
- Trial name
- NCT05473910
- Testing
- SOC + TSC-101, Control, SOC + TSC-100
- Where
- 21 sites in United States
- Volunteers
- 310 people
- Sponsor
- TScan Therapeutics, Inc.
CMV
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT).
- Trial name
- INMUNOCELL (NCT04056533)
- Testing
- CMV CTLs
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT02508038
- Testing
- TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Acute Myeloid Leukemia
FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML
Acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) predominantly affect older adults, and their incidence continues to rise with advanced age.
- Trial name
- FT-RIC-HAPLO (NCT07598110)
- Testing
- fludarabine and treosulfan
- Volunteers
- 77 people
- Sponsor
- Institut Paoli-Calmettes
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia
Feasibility and toxicity of haploidentical allogeneic HCT after a reduced intensity conditioning regimen with CD3/CD19 depleted grafts.
- Trial name
- CD3/CD19 Haplo (NCT00961142)
- Testing
- Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)
- Where
- 8 sites in Germany
- Volunteers
- 23 people
- Sponsor
- University Hospital Tuebingen
Thalassemia Major
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
The purpose of the study is to assess the safety and efficacy of haploidentical hematopoietic stem cell transplantation for patients with thalassemia major.
- Trial name
- NCT03171831
- Testing
- Busulfan, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Lymphoma
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
The goal of this clinical research study is to study the safety of ADCETRISTM (brentuximab vedotin) in patients with Hodgkin lymphoma or ALCL who have had an allogeneic or haploidentical stem cell transplant.
- Trial name
- NCT02169505
- Testing
- Brentuximab Vedotin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease, Leukemia
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell and donor natural killer cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00450983
- Testing
- muromonab-CD3, natural killer cell therapy, fludarabine phosphate
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Haploidentical Hematopoietic Stem Cell Transplantation
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.
- Trial name
- NCT06041893
- Testing
- ATG-LDPTCy
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
Study CR-AIR-006 is a part of the ATIR clinical development plan and will provide control data for patients treated with ATIR in clinical studies (e.g. study CR-AIR-007).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02188290
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 178 people
- Sponsor
- Kiadis Pharma
Graft Versus Host Disease, Leukemia
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, together with antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00740467
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Paoli-Calmettes
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
This trial investigates stem cell transplants from partially mismatched donors in patients with blood and bone marrow cancers. The trial will test two kinds of transplants - a full intensity transplant using a high dose of…
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Myeloid Leukaemia, Acute Lymphoblastic Leukaemia
- Trial name
- UK-Haplo (NCT01597219)
- Testing
- Reduced intensity haplodentical stem cell transplant, Myeloablative haploidentical stem cell transplant
- Where
- 12 sites in United Kingdom
- Volunteers
- 77 people
- Sponsor
- University College, London
Malignant and Non-malignant High Risk Diseases
Allogeneic Stem Cell Transplantation in Pediatric Patients With Malignant and Non-malignant High-risk Diseases
The aim of the study is to investigate the feasibility and toxicity of allogeneic haploidentical or unrelated transplantation with CD3/CD19 depleted stem cells associated with a reduced or a standard conditioning regimen in…
- Trial name
- NCT00945126
- Testing
- Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Graft Vs Host Disease, Graft-versus-host-disease
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies.
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
- Trial name
- NCT06008808
- Testing
- Ruxolitinib, Abatacept
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Washington University School of Medicine
Primary Immune Deficiency Disorders, Metabolic Disease
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition.
- Trial name
- NCT04414046
- Testing
- Haploidentical Hematopoietic Cell Transplantation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Johns Hopkins All Children's Hospital
Acute Leukemia
A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia
The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias.
- Trial name
- Gandalf-01 (NCT01814488)
- Testing
- allogeneic transplant
- Where
- 30 sites in Italy
- Volunteers
- 101 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Hematopoietic Cell Transplantation
Randomised Controlled Trial Comparing CD62L and CD45RA Depleted Donor Lymphocyte Infusion With T-cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation
The goal of clinical trial is to compare the efficacy and safety of CD62L depleted donor lymphocyte infusion (DLI) with CD45RA depleted DLI in children who receive T-cell depleted haploidentical hematopoietic stem cell…
- Trial name
- NCT07867769
- Testing
- CD62L depleted DLI, CD45RA depleted DLI, Haploidentical HSCT
- Where
- Hong Kong
- Volunteers
- 46 people
- Sponsor
- Hong Kong Children's Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT00789776
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Benign Neoplasm, Bone Marrow Transplantation Recipient
Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders
This expanded access protocol studies bone marrow transplantation using CD34-selected stem cells from related or unrelated donors in treating participants with cancer or other disorders.
- Conditions
- Benign Neoplasm, Bone Marrow Transplantation Recipient, Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm
- Trial name
- NCT03626285
- Testing
- Bone Marrow Transplantation, CliniMACS CD34 Reagent System, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Sponsor
- OHSU Knight Cancer Institute